Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/05/25
New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal CancerGlobeNewsWire • 05/02/25
New Study Shows Castle Biosciences' DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node PositivityGlobeNewsWire • 04/30/25
DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous MelanomaGlobeNewsWire • 04/28/25
New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant MetastasisGlobeNewsWire • 04/25/25
Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative PartnershipsGlobeNewsWire • 04/08/25
Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive YearGlobeNewsWire • 04/07/25
Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences' DecisionDx®-Melanoma TestGlobeNewsWire • 04/03/25
Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with MelanomaGlobeNewsWire • 04/01/25
Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk GroupsGlobeNewsWire • 03/28/25
New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology PortfolioBusiness Wire • 03/07/25
Castle Biosciences, Inc. (CSTL) Surpasses Q4 Earnings and Revenue EstimatesZacks Investment Research • 02/28/25
Castle Biosciences, Inc. (CSTL) Reports Next Week: Wall Street Expects Earnings GrowthZacks Investment Research • 02/20/25
Wall Street Analysts See a 50.79% Upside in Castle Biosciences (CSTL): Can the Stock Really Move This High?Zacks Investment Research • 02/20/25
Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii®Business Wire • 02/12/25
Surging Earnings Estimates Signal Upside for Castle Biosciences (CSTL) StockZacks Investment Research • 02/12/25
Castle Biosciences to Release Fourth Quarter and Full-Year 2024 Financial Results and Host Conference Call on Thursday, Feb. 27, 2025Business Wire • 02/06/25